Irbesartan Eg

Irbesartan, the active ingredient in Irbesartan Eg, is a Angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It is used to treat hypertension and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an angiotensin II receptor blocker used to manage conditions related to the renin‑angiotensin system. - Hypertension: lowers elevated blood pressure and reduces cardiovascular risk. - Diabetic nephropathy: slows the progression of kidney damage in type‑2 diabetes. - Chronic kidney disease with hypertension: helps control blood pressure and proteinuria, supporting renal preservation.

Irbesartan may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness: feeling light‑headed, especially after standing. - Headache: mild to moderate intensity. - Fatigue: general tiredness or lack of energy. - Nasal congestion: stuffy or runny nose. - Hyperkalemia: elevated blood potassium levels. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat. - Acute renal failure: sudden loss of kidney function. - Severe hyperkalemia: dangerously high potassium that may affect heart rhythm. - Hepatic injury: signs of liver dysfunction such as jaundice. - Myocardial infarction: rare reports of heart attack. - Anaphylactic reaction: severe allergic response requiring immediate medical attention.

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid hypotension. - Renal function: assess serum creatinine and eGFR before and during treatment. - Electrolytes: monitor potassium levels, especially in patients on potassium‑sparing agents. - Hepatic impairment: use with caution in patients with liver disease. - Pregnancy: avoid use; teratogenic risk is unknown. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Irbesartan can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Aliskiren (in diabetes): combined use may increase renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics (e.g., spironolactone): risk of severe hyperkalemia. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: may blunt antihypertensive effect and impair renal function. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive effect. - Cyclosporine: can increase serum irbesartan levels. - Rifampin: may reduce irbesartan concentrations. - Digoxin: monitor for signs of toxicity as plasma levels may rise.